|Systematic IUPAC name
N-Carbamimidoyl-N-methylglycine; Methylguanidoacetic acid
3D model (JSmol)
|Molar mass||131.14 g·mol−1|
|Melting point||255 °C (491 °F; 528 K)|
|13.3 g L−1 (at 18 °C)|
|171.1 J K−1 mol−1 (at 23.2 °C)|
|189.5 J K−1 mol−1|
Std enthalpy of
|−538.06–−536.30 kJ mol−1|
Std enthalpy of
|−2.3239–−2.3223 MJ mol−1|
|GHS signal word||WARNING|
|H315, H319, H335|
Related alkanoic acids
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Creatine (// or //) is a nitrogenous organic acid that occurs naturally in vertebrates. Its main role is to facilitate recycling of adenosine triphosphate (ATP), the energy currency of the cell, primarily in muscle and brain tissue. This is achieved by recycling adenosine diphosphate (ADP) to ATP via donation of phosphate groups. Creatine also acts as a pH buffer in tissues.
Creatine synthesis primarily occurs in the liver and kidneys. On average, it is produced endogenously at an estimated rate of about 8.3 mmol or 1 gram per day in young adults. Creatine is also obtained through the diet at a rate of about 1 gram per day from an omnivorous diet. Most of the human body's total creatine and phosphocreatine stores are found in skeletal muscle, while the remainder is distributed in the blood, brain, and other tissues.
Creatine was identified in 1832 when Michel Eugène Chevreul isolated it from the basified water-extract of skeletal muscle. He later named the crystallized precipitate after the Greek word for meat, κρέας (kreas). In solution, creatine is in equilibrium with creatinine. Creatine is a derivative of the guanidinium cation.
Creatine is not an essential nutrient as it is naturally produced in the human body from the amino acids glycine and arginine. In the first step of the biosynthesis these two amino acids are combined by the enzyme arginine:glycine amidinotransferase (AGAT, EC:126.96.36.199) to form guanidinoacetate, which is then methylated by guanidinoacetate N-methyltransferase (GAMT,EC:188.8.131.52), using S-adenosyl methionine as the methyl donor. Creatine itself can be phosphorylated by creatine kinase to form phosphocreatine, which is used as an energy buffer in skeletal muscles and the brain.
Synthesis primarily takes place in the kidney and liver, with creatine then being transported to the muscles via the blood. The majority of the human body's total creatine and phosphocreatine stores are located in skeletal muscle, while the remainder is distributed in the blood, brain, and other tissues. On average, creatine is produced endogenously at an estimated rate of about 8.3 mmol or 1 gram per day in young adults. Creatine is also obtained through the diet at a rate of about 1 gram per day from an omnivorous diet. Some small studies suggest that total muscle creatine is significantly lower in vegetarians than non-vegetarians, as expected since vegetables are not a primary source of creatine. However, subjects happened to show the same levels after using supplements. Given that creatine can be synthesized from the above-mentioned amino acids, protein sources rich in these amino acids can be expected to provide sufficient native biosynthesis in the body.
Genetic deficiencies in the creatine biosynthetic pathway lead to various severe neurological defects. Clinically, there are three distinct disorders of creatine metabolism. Deficiencies in the two synthesis enzymes can cause L-arginine:glycine amidinotransferase deficiency and guanidinoacetate methyltransferase deficiency. Both biosynthetic defects are inherited in an autosomal recessive manner. A third defect, creatine transporter defect is caused by mutations in SLC6A8 and inherited in a X-linked manner. This condition is related to the transport of creatine into the brain.
Creatine, synthesized in the liver and kidney, is transported through the blood and taken up by tissues with high energy demands, such as the brain and skeletal muscle, through an active transport system. The concentration of ATP in skeletal muscle is usually 2-5 mM, which would result in a muscle contraction of only a few seconds. Fortunately, during times of increased energy demands, the phosphagen (or ATP/PCr) system rapidly resynthesizes ATP from ADP with the use of phosphocreatine (PCr) through a reversible reaction with the enzyme creatine kinase (CK). In skeletal muscle, PCr concentrations may reach 20-35 mM or more. Additionally, in most muscles, the ATP regeneration capacity of CK is very high and is therefore not a limiting factor. Although the cellular concentrations of ATP are small, changes are difficult to detect because ATP is continuously and efficiently replenished from the large pools of PCr and CK. Creatine has the ability to increase muscle stores of PCr, potentially increasing the muscle’s ability to resynthesize ATP from ADP to meet increased energy demands.
Creatine supplements are used by athletes, bodybuilders, wrestlers, sprinters, and others who wish to gain muscle mass. The Mayo Clinic states that creatine has been associated with asthmatic symptoms and warns against consumption by persons with known allergies to creatine.
There are reports of kidney damage with creatine use, such as interstitial nephritis; patients with kidney disease should avoid use of this supplement. In similar manner, liver function may be altered, and caution is advised in those with underlying liver disease, although studies have shown little or no adverse impact on kidney or liver function from oral creatine supplementation. In 2004 the European Food Safety Authority (EFSA) published a record which stated that oral long-term intake of 3 g pure creatine per day is risk-free. A 2003 study on athletes who took creatine for 21 months found no significant changes in markers of kidney function; a 2008 study on athletes who took creatine for 3 months found no evidence of kidney damage during that time. A review found creatine to have no effects on liver of kidney function in over months of supplementation in both young and old population. However authors still cautioned against using high doses(>3g-5g) in those with impaired kidney functioning, and suggested further studies are needed relating to claims of mutagenicity and carcinogenicity.
Long-term administration of large quantities of creatine is reported to increase the production of formaldehyde, which has the potential to cause serious unwanted side effects. However, this risk is largely theoretical because urinary excretion of formaldehyde, even under heavy creatine supplementation, does not exceed normal limits.
Extensive research has shown that oral creatine supplementation at a rate of five to 20 grams per day appears to be very safe and largely devoid of adverse side-effects, while at the same time effectively improving the physiological response to resistance exercise, increasing the maximal force production of muscles in both men and women.
While some research indicates that supplementation with pure creatine is safe, a survey of 33 commercially available in Italy supplements found that over 50% of them exceeded the European Food Safety Authority recommendations in at least one contaminant. The most prevalent of these contaminants was creatinine, a breakdown product of creatine also produced by the body. Creatinine was present in higher concentrations than the European Food Safety Authority recommendations in 44% of the samples. About 15% of the samples had detectable levels of dihydro-1,3,5-triazine or a high dicyandiamide concentration. Heavy metals contamination was not found to be a concern, with only minor levels of mercury being detectable. Two studies reviewed in 2007 found no impurities.
Endogenous serum or plasma creatine concentrations in healthy adults are normally in a range of 2–12 mg/L. A single 5 g (5000 mg) oral dose in healthy adults results in a peak plasma creatine level of approximately 120 mg/L at 1–2 hours post-ingestion. Creatine has a fairly short elimination half-life, averaging just less than 3 hours, so to maintain an elevated plasma level it would be necessary to take small oral doses every 3–6 hours throughout the day. After the "loading dose" period (1–2 weeks, 12-24 g a day), it is no longer necessary to maintain a consistently high serum level of creatine. As with most supplements, each person has their own genetic "preset" amount of creatine they can hold. The rest is eliminated as waste. A typical post-loading dose is 2-5 g daily.
Pregnancy and breastfeeding
While research is limited, some recent retrospective studies show higher maternal serum creatine to correlate with higher birth weight and better birth outcomes. However, as of 2014, there were no randomised controlled trials establishing its effectiveness when supplemented, for neuroprotection of the fetus.
A meta analysis found that creatine treatment increased muscle strength in muscular dystrophies, and potentially improved functional performance. Creatine treatment does not appear to improve muscle strength in people who have metabolic myopathies. High doses of creatine leads to increased muscle pain and an impairment in activities of daily living when taken by people who have McArdle disease. It has also been implicated in decreasing mutagenesis in DNA.
When creatine is mixed with protein and sugar at high temperatures (above 148 °C), the resulting reaction produces heterocyclic amines (HCAs). Such a reaction happens when grilling or pan frying meat. Creatine content (as a percentage of crude protein) can be used as an indicator of meat quality.
A Meta-analysis from 2011 concluded that "search for the excretion of heterocyclic amines remains a future task to definitively exclude the unproved allegation made by some national agencies".
- Entry "creatine" in Merriam-Webster Online Dictionary.
- Wells, J. C. (2000). Longman Pronunciation Dictionary. Harlow, England: Pearson Education Ltd.
- Barcelos RP, Stefanello ST, Mauriz JL, Gonzalez-Gallego J, Soares FA (2016). "Creatine and the Liver: Metabolism and Possible Interactions". Mini Rev Med Chem. 16 (1): 12–8. PMID 26202197.
The process of creatine synthesis occurs in two steps, catalyzed by L-arginine:glycine amidinotransferase (AGAT) and guanidinoacetate N-methyltransferase (GAMT), which take place mainly in kidney and liver, respectively. This molecule plays an important energy/pH buffer function in tissues, and to guarantee the maintenance of its total body pool, the lost creatine must be replaced from diet or de novo synthesis.
- Brosnan JT, da Silva RP, Brosnan ME (2011). "The metabolic burden of creatine synthesis". Amino Acids. 40 (5): 1325–31. PMID 21387089. doi:10.1007/s00726-011-0853-y.
Creatinine loss averages approximately 2 g (14.6 mmol) for 70 kg males in the 20- to 39-year age group. ... Table 1 Comparison of rates of creatine synthesis in young adults with dietary intakes of the three precursor amino acids and with the whole body transmethylation flux
Creatine synthesis (mmol/day) 8.3
- Cooper R, Naclerio F, Allgrove J, Jimenez A (2012). "Creatine supplementation with specific view to exercise/sports performance: an update". J Int Soc Sports Nutr. 9 (1): 33. PMC . PMID 22817979. doi:10.1186/1550-2783-9-33.
Creatine is produced endogenously at an amount of about 1 g/d. Synthesis predominately occurs in the liver, kidneys, and to a lesser extent in the pancreas. The remainder of the creatine available to the body is obtained through the diet at about 1 g/d for an omnivorous diet. 95% of the bodies creatine stores are found in the skeletal muscle and the remaining 5% is distributed in the brain, liver, kidney, and testes .
- Brosnan ME, Brosnan JT (2016). "The role of dietary creatine". Amino Acids. 48 (8): 1785–91. PMID 26874700. doi:10.1007/s00726-016-2188-1.
The daily requirement of a 70-kg male for creatine is about 2 g; up to half of this may be obtained from a typical omnivorous diet, with the remainder being synthesized in the body ... More than 90% of the body’s creatine and phosphocreatine is present in muscle (Brosnan and Brosnan 2007), with some of the remainder being found in the brain (Braissant et al. 2011). ... Creatine synthesized in liver must be secreted into the bloodstream by an unknown mechanism (Da Silva et al. 2014a)
- Cannan, R. K.; Shore, A. (1928). "The creatine-creatinine equilibrium. The apparent dissociation constants of creatine and creatinine" (PDF). Biochem. J. 22 (4): 920–29. PMC . PMID 16744118. Retrieved 2010-10-29.
- "Creatine". Beth Israel Deaconess Medical Center. Retrieved 2010-08-23.
- "Creatine". MedLine Plus Supplements. U.S. National Library of Medicine. 20 July 2010. Retrieved 2010-08-16.
Creatine is a chemical that is normally found in the body, mostly in muscles but also in the brain.
- Burke DG, Chilibeck PD, Parise G, Candow DG, Mahoney D, Tarnopolsky M; Chilibeck; Parise; Candow; Mahoney; Tarnopolsky (2003). "Effect of creatine and weight training on muscle creatine and performance in vegetarians". Medicine and science in sports and exercise. 35 (11): 1946–55. PMID 14600563. doi:10.1249/01.MSS.0000093614.17517.79.
- "L-Arginine:Glycine Amidinotransferase". Retrieved 2010-08-16.
- Braissant, O; Henry, H; Béard, E; Uldry, J (May 2011). "Creatine deficiency syndromes and the importance of creatine synthesis in the brain.". Amino Acids. 40 (5): 1315–24. PMID 21390529. doi:10.1007/s00726-011-0852-z.
- Wallimann, T; Wyss, M; Brdiczka, D; Nicolay, K; Eppenberger, HM (January 1992). "Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis". The Biochemical Journal. 281 (Pt 1): 21–40. PMC . PMID 1731757. doi:10.1042/bj2810021.
- Spillane, M; Schoch, R; Cooke, M; Harvey, T; Greenwood, M; Kreider, R; Willoughby, DS (2009). "The effects of creatine ethyl ester supplementation combined with heavy resistance training on body composition, muscle performance, and serum and muscle creatine levels". Journal of the International Society of Sports Nutrition. 6 (1): 6. PMC . PMID 19228401. doi:10.1186/1550-2783-6-6.
- Wallimann, T; Tokarska-Schlattner, M; Schlattner, U (May 2011). "The creatine kinase system and pleiotropic effects of creatine". Amino Acids. 40 (5): 1271–96. PMC . PMID 21448658. doi:10.1007/s00726-011-0877-3..
- T. Wallimann, M. Tokarska-Schlattner, D. Neumann u. a.: The Phosphocreatine Circuit: Molecular and Cellular Physiology of Creatine Kinases, Sensitivity to Free Radicals, and Enhancement by Creatine Supplementation. In: Molecular System Bioenergetics: Energy for Life. 22. November 2007. doi:10.1002/9783527621095.ch7C
- "Creatine: Safety". MayoClinic.com. Retrieved 2010-08-16.
- Lopez RM, Casa DJ, McDermott BP, Ganio MS, Armstrong LE, Maresh CM; Casa; McDermott; Ganio; Armstrong; Maresh (2009). "Does Creatine Supplementation Hinder Exercise Heat Tolerance or Hydration Status? A Systematic Review With Meta-Analyses". Journal of Athletic Training. 44 (2): 215–23. PMC . PMID 19295968. doi:10.4085/1062-6050-44.2.215.
- Dalbo VJ, Roberts MD, Stout JR, Kerksick CM; Roberts; Stout; Kerksick (July 2008). "Putting to rest the myth of creatine supplementation leading to muscle cramps and dehydration". British Journal of Sports Medicine. 42 (7): 567–73. PMID 18184753. doi:10.1136/bjsm.2007.042473.
- Poortmans JR, Francaux M; Francaux (September 2000). "Adverse effects of creatine supplementation: fact or fiction?". Sports Medicine. 30 (3): 155–70. PMID 10999421. doi:10.2165/00007256-200030030-00002.
- Kreider, Richard B.; Melton, Charles; Rasmussen, Christopher J.; Greenwood, Michael; Lancaster, Stacy; Cantler, Edward C.; Milnor, Pervis; Almada, Anthony L. (2003). "Long-term creatine supplementation does not significantly affect clinical markers of health in athletes". Molecular and Cellular Biochemistry. 244 (1–2): 95–104. PMID 12701816. doi:10.1023/A:1022469320296.
- Gualano, Bruno; Ugrinowitsch, Carlos; Novaes, Rafael Batista; Artioli, Guilherme Gianini; Shimizu, Maria Heloisa; Seguro, Antonio Carlos; Harris, Roger Charles; Lancha, Antonio Herbert (2008). "Effects of creatine supplementation on renal function: A randomized, double-blind, placebo-controlled clinical trial". European Journal of Applied Physiology. 103 (1): 33–40. PMID 18188581. doi:10.1007/s00421-007-0669-3.
- Kim, Hyo Jeong; Kim, Chang Keun; Carpentier, A.; Poortmans, Jacques R. (1 May 2011). "Studies on the safety of creatine supplementation". Amino Acids. 40 (5): 1409–1418. ISSN 1438-2199. PMID 21399917. doi:10.1007/s00726-011-0878-2.
- Francaux M, Poortmans JR; Poortmans (December 2006). "Side effects of creatine supplementation in athletes". International Journal of Sports Physiology and Performance. 1 (4): 311–23. PMID 19124889.
- "International Society of Sports Nutrition position stand: creatine supplementation and exercise". jissn. Retrieved 19 January 2012.
- Bizzarini E, De Angelis L; De Angelis (December 2004). "Is the use of oral creatine supplementation safe?". The Journal of Sports Medicine and Physical Fitness. 44 (4): 411–6. PMID 15758854.
- Bemben MG, Lamont HS; Lamont (2005). "Creatine supplementation and exercise performance: recent findings". Sports Medicine. 35 (2): 107–25. PMID 15707376. doi:10.2165/00007256-200535020-00002.
- Kreider RB (February 2003). "Effects of creatine supplementation on performance and training adaptations" (PDF). Molecular and Cellular Biochemistry. 244 (1–2): 89–94. PMID 12701815. doi:10.1023/A:1022465203458.
- Persky, AM; Rawson, ES (2007). "Safety of creatine supplementation.". Sub-cellular biochemistry. 46: 275–89. PMID 18652082. doi:10.1007/978-1-4020-6486-9_14.
- Kim HJ, Kim CK, Carpentier A, Poortmans JR (2011). "Studies on the safety of creatine supplementation". Amino Acids (Review). 40 (5): 1409–18. PMID 21399917. doi:10.1007/s00726-011-0878-2.
- Pastula, DM; Moore, DH; Bedlack, RS (12 December 2012). "Creatine for amyotrophic lateral sclerosis/motor neuron disease.". The Cochrane database of systematic reviews. 12: CD005225. PMID 23235621. doi:10.1002/14651858.CD005225.pub3.
- Moreta S, Prevarin A, Tubaro F.; Prevarin; Tubaro (June 2011). "Levels of creatine, organic contaminants and heavy metals in creatine dietary supplements". Food Chemistry. 126 (3): 1232–1238. doi:10.1016/j.foodchem.2010.12.028.
- Jäger R, Harris RC, Purpura M, Francaux M (2007). "Comparison of new forms of creatine in raising plasma creatine levels". J Int Soc Sports Nutr. 4: 17. PMC . PMID 17997838. doi:10.1186/1550-2783-4-17.
- Kamber M, Koster M, Kreis R, Walker G, Boesch C, Hoppeler H. Creatine supplementation--part I: performance, clinical chemistry, and muscle volume. Med. Sci. Sports Exer. 31: 1763-1769, 1999.
- Deldicque, L; Décombaz, J; Zbinden Foncea, H; Vuichoud, J; Poortmans, JR; Francaux, M (2008). "Kinetics of creatine ingested as a food ingredient". Eur. J. Appl. Physiol. 102: 133–143. PMID 17851680. doi:10.1007/s00421-007-0558-9.
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 366-368.
- Hülsemann J, Manz F, Wember T, Schöch G; Manz; Wember; Schöch (1987). "[Administration of creatine and creatinine with breast milk and infant milk preparations]". Klinische Pädiatrie (in German). 199 (4): 292–5. PMID 3657037. doi:10.1055/s-2008-1026805.
- Wallimann, Theo; Tokarska-Schlattner, Malgorzata; Schlattner, Uwe (1 May 2011). "The creatine kinase system and pleiotropic effects of creatine". Amino Acids. Springer Wien. 40 (5): 1271–1296. ISSN 0939-4451. PMC . PMID 21448658. doi:10.1007/s00726-011-0877-3.
- Kley, Rudolf A.; Tarnopolsky, Mark A.; Vorgerd, Matthias (2013-06-05). "Creatine for treating muscle disorders". The Cochrane Database of Systematic Reviews (6): CD004760. ISSN 1469-493X. PMID 23740606. doi:10.1002/14651858.CD004760.pub4.
- Rahimi, R. (2011). "Creatine Supplementation Decreases Oxidative DNA Damage and Lipid Peroxidation Induced by a Single Bout of Resistance Exercise". Journal of Strength and Conditioning Research. 25 (12): 3448–3455. PMID 22080314. doi:10.1519/JSC.0b013e3182162f2b.
- "Chemicals in Meat Cooked at High Temperatures and Cancer Risk". National Cancer Institute.
- Dahl, Olle (1 July 1963). "Meat Quality Measurement, Creatine Content as an Index of Quality of Meat Products". Journal of Agricultural and Food Chemistry. 11 (4): 350–355. doi:10.1021/jf60128a026 – via ACS Publications.